Publications dont lesquelles l'un de nos scientifiques est impliqué :
- Pharmacokinetics, Safety, and Efficacy of Gadopiclenol in Pediatric Patients Aged 2 to 17 Years. Jurkiewicz E, Tsvetkova S, Grinberg A, Pasquiers B. Investigative Radiology: August 2022 - Volume 57 - Issue 8 - p 510-516. doi: 10.1097/RLI.0000000000000865 https://.doi.org/10.1097/RLI.0000000000000865
- Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. Hirt D, Oualha M, Pasquiers B, Blanot S, Rubinstazjn R, Glorion C, Messaoudi SE, Drummond D, Lopez V, Toubiana J, Béranger A, Boujaafar S, Zheng Y, Capito C, Winter S, Léger PL, Berthaud R, Gana I, Foissac F, Tréluyer JM, Bouazza N, Benaboud S. (2021). Eur J Clin Pharmacol. 2021 Nov;77(11):1687-1695. https://doi.org/10.1007/s00228-021-03174-1
- PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus. Szeto, K. X., Le Merdy, M., Dupont, B., Bolger, M. B., & Lukacova, V. (2021). The AAPS journal, 23(4), 89. https://doi.org/10.1208/s12248-021-00603-y
- Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. Dubourg, J., Perrimond-Dauchy, S., Felices, M., Bolze, S., Voiriot, P., & Fouqueray, P. (2020). European Journal of Clinical Pharmacology, 76(10), 1393-1400. doi:10.1007/s00228-020-02929-6
https://pubmed.ncbi.nlm.nih.gov/32556539/ - Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects. Funck‐Brentano, C., Felices, M., Fur, N. L., Dubourdieu, C., Desché, P., Vanhoutte, F., & Voiriot, P. (2020). British Journal of Clinical Pharmacology, 86(11), 2174-2181. doi:10.1111/bcp.14309
https://pubmed.ncbi.nlm.nih.gov/32302009/ - Bioequivalence study of two Ibuprofen formulations administered intravenously in healthy male volunteers Chassard D, Geneteau A, Gualano V, Brault M. Clin. Drug. Invest. 24(12): 739-747, 2004
http://www.ncbi.nlm.nih.gov/pubmed/17523737 - Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency Chatelut E, Rostaing L, Gualano V, Vissac T, De Forni M, Ton-That H, Suc JM, Houin G, Canal P. Nephron. 66(2):157-61, 1994
http://www.ncbi.nlm.nih.gov/pubmed/8139735 - Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers de Forni M, Gualano V, Canal P, Martel P, Izar-Soum F, Chevreau C, Soulie P, Roche H, Bugat R. Bull Cancer 80(5):408-17, 1993 (French)
http://www.ncbi.nlm.nih.gov/pubmed/8173194 - Comparative bioavailability study of two omeprazole formulations after single and repeated administrations Duvauchelle T., Millérioux L., Gualano V. Evène E., Alcaïde A., Clin. Drug Investigation, 16, 141 –149, 1998
http://www.ncbi.nlm.nih.gov/pubmed/18370532 - Population pharmacokinetics of ibuprofen enantiomers in very premature neonates Grégoire N, Gualano V, Geneteau A, Millerioux L, Brault M, Mignot A, Roze J.C. J Clin Pharmacol. 44: 1114-24, 2004
http://www.ncbi.nlm.nih.gov/pubmed/15342612 - Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose Gregoire N, Hovsepian L, Gualano V, Evène E, Dufour G, Gendron A. Clin. Pharm; Ther., 81(3):401-5, 2007
http://www.ncbi.nlm.nih.gov/pubmed/17339870 - Comparative bioavailability of two oral nimodipine formulations after administration to 24 healthy volunteers Gualano V, Ntssikoussalabongui B, Mignot A, Duvauchelle T, Felices M, Guillaume M, Orlandini B, Holguin J, Alcaïde A.. Clin. Drug Investig. 17; 6: 475-82, 1999
http://www.ingentaconnect.com/content/adis/cdi/1999/00000017/00000006/art00008 Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers Mignot A, Guillaume M, Brault M, Gualano V, Millerioux L, Gohler K, Stahlberg HJ. Chemotherapy. 48(3):116-21, 2002
http://www.ncbi.nlm.nih.gov/pubmed/12138326High-performance liquid chromatographic determination of baclofen in human plasma Millerioux L, Brault M, Gualano V, Mignot A. J Chromatogr A. 5;729(1-2):309-14, 1996
http://www.ncbi.nlm.nih.gov/pubmed/9004955Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study Montastruc JL, Rascol O, Senard JM, Gualano V, Bagheri H, Houin G, Lees A, Rascol A. Clin. Neuropharmacol. , 14(5):432-7, 1991
http://www.ncbi.nlm.nih.gov/pubmed/1742752Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G. Cancer Chemother Pharmacol.; 32(5): 379-84, 1993
http://www.ncbi.nlm.nih.gov/pubmed/8339389Pharmacokinetics and tolerability of prulifloxacin after single oral administration Picollo R, Brion N, Gualano V, Millerioux L, Marchetti M, Rosignoli MT, Dionisio P. Arzneimittelforschung; 53(3):201-5, 2003
http://www.ncbi.nlm.nih.gov/pubmed/12705176Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men Raynaud JP, Aumonier C, Gualano V, Betea D, Beckers A. J Steroid Biochem Mol Biol, 109(1-2):177-84, 2008
http://www.ncbi.nlm.nih.gov/pubmed/18325758Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch Santoro A, Rovati LC, Follet M, Setnikar I, Caplain H, Gualano V. Arzneimittelforschung;50(9):786-94, 2000
http://www.ncbi.nlm.nih.gov/pubmed/11050694Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch Santoro A, Rovati LC, Setnikar I, Caplain H, Gualano V. Arzneimittelforschung, 50(9): 779-85, 2000
http://www.ncbi.nlm.nih.gov/pubmed/11050693Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch Setnikar I, Rovati LC, Santoro A, Guillaume M, Mignot A, Renoux A, Gualano V. Arzneimittelforschung; 49(8): 708-15, 1999
http://www.ncbi.nlm.nih.gov/pubmed/10483519Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix Setnikar I, Rovati LC, Thebault JJ, Guillaume M, Mignot A, Renoux A, Gualano V. Arzneimittelforschung, 47(7):859-65, 1997
http://www.ncbi.nlm.nih.gov/pubmed/9272245Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C. Cancer Chemother Pharmacol. 1998
http://www.ncbi.nlm.nih.gov/pubmed/9488597Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. Dirix L, Catimel G, Koier I, Provè A, Schrijvers D, Joossens E, De Bruijn E, Ardiet C, Evene E, Dumortier A, et al. Anticancer Drugs. 1995
http://www.ncbi.nlm.nih.gov/pubmed/7756684A single-center, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (Zindaclin) and topical clindamycin lotion (Dalacin® T) in subjects with mild to moderate acne Chassard D, Kanis R, Namour F, Evène E, Ntssikoussalabongui B, Schmitz V., J Dermatolog Treat, 17(3): 154-157, 2006
http://www.ncbi.nlm.nih.gov/pubmed/16854755Bayesian estimation of pharmacokinetic parameters of etoposide Evène E., Tranchand B., Chatelut E., Canal P., Ardiet C.. Bulletin du Cancer, 84, 699 – 703, 1997(French)
http://www.ncbi.nlm.nih.gov/pubmed/9339195Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F. J Antimicrob Chemother, 63(3):585-92, 2009
http://www.ncbi.nlm.nih.gov/pubmed/19147519Bioequivalence study of two formulations (sachet and tablet) of cefixime after single oral doses of 200 mg in healthy male volunteers. Evène E., Brault M., Manche M., Sibille M., Montay G., Vital Durand D., Clin. Drug Investigation, 21, 287 – 94, 2001
http://www.ingentaconnect.com/content/adis/cdi/2001/00000021/00000004/art00007Pharmacokinetics of repaglinide in healthy Caucasian and Japanese Subjects Thomsen M.S., Chassard D., Evène E., K.K. Nielsen, M. Jørgensen., J Clin Pharmacol, 43, 23-28, 2003
http://www.ncbi.nlm.nih.gov/pubmed/12520624Phase I pharmacokinetic study of high dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas Tranchand B., Lucas C., Biron P., Giroux B., Gordon B., Richards R., Solere P., Roux N., Evène E., Mornex F., Clavel M., Ardiet C. Cancer Chemother. Pharmacol., 32, 46 – 52, 1993
http://www.ncbi.nlm.nih.gov/pubmed/8462123Statistical investigation of the full concentration range of fasted and fed simulated intestinal fluid on the equilibrium solubility of oral drugs Jeremy Perrier, Zhou Zhou, Claire Dunn, Ibrahim Khadra, Clive G Wilson, Gavin Halbert European Journal of Pharmaceutical Sciences. Elsevier, 111(June 2017), pp. 247–256
https://www.ncbi.nlm.nih.gov/pubmed/28987539Dual level statistical investigation of equilibrium solubility in simulated fasted and fed intestinal fluid. Bayan E Ainousah, Jeremy Perrier, Zhou Zhou, Claire Dunn, Ibrahim Khadra, Clive G Wilson, Gavin Halbert Mol. Pharmaceutics, 2017, 14 (12), pp 4170-4180
https://www.ncbi.nlm.nih.gov/pubmed/29072917The topography of simulated intestinal equilibrium solubility Claire Dunn, Jeremy Perrier, Zhou Zhou, Ibrahim Khadra, Clive G Wilson, Gavin Halbert Mol. Pharm. 2019 May 6;16(5):1890-1905
https://www.ncbi.nlm.nih.gov/pubmed/30848917Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation Christian Funck-Brentano, Antonella Bacchieri, Giovanni Valentini, Silvia Pace, Silva Tommasini, Pascal Voiriot, David Ubben, Stephan Duparc, Eric Evene, Mathieu Felices & Marco Corsi Scientific Reports 9(1):883 · December 2019
https://www.nature.com/articles/s41598-018-37112-6Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method Christian Funck-Brentano, Nouhoum Ouologuem, Stephan Duparc, Mathieu Felices, Sodiomon B. Sirima, Issaka Sagara, Issiaka Soulama, Jean-Bosco Ouedraogo, Abdoul H. Beavogui, Isabelle Borghini-Fuhrer, Yasmin Khan, Abdoulaye A. Djimdé & Pascal Voiriot Sci Rep. 2019 Jan 29;9(1):883
https://www.ncbi.nlm.nih.gov/pubmed/30696921Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist Rashmi R Shah, Pierre Maison-Blanche, Philippe Robert, Emmanuel Denis, Thierry Duvauchelle Eur J Clin Pharmacol. 2016 May;72(5):533-43
https://www.ncbi.nlm.nih.gov/pubmed/26879827A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years Mario Scala, Meriam Koob, Sophie de Buttet, Philippe Bourrinet, Mathieu Felices and Elzbieta Jurkiewicz Invest Radiol. 2018 Feb;53(2):70-79
https://www.ncbi.nlm.nih.gov/pubmed/28906338Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies Antoine Tarral, Séverine Blesson, Olaf Valverde Mordt, Els Torreele, Daniela Sassella, Michael A. Bray, Lionel Hovsepian, Eric Evène, Virginie Gualano, Mathieu Felices, and Nathalie Strub-Wourgaft Clin Pharmacokinet. 2014; 53(6): 565–580.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037587/
